1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Dong-A ST Co., Ltd.

Dong-A ST Co., Ltd.

KKRX:170900
34,600.00
KRW
-400.00
(-1.14%)
597.59EPS
37.61P/E
327.41BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
61,553.47
68,930.34
64,989.75
60,016.56
58,991.62
60,342.89
65,124.43
62,403.08
63,100.38
68,927.64
73,048.45
76,842.96
84,024.32
89,428.22
Basic EPS, GAAP
-8,074.36
4,456.74
5,557.01
1,137.97
-573.47
851.68
7,542.17
2,882.61
1,363.23
1,470.13
1,223.65
-134.67
-2,970.48
902.68
Free Cash Flow per Basic Share
-6,168.3
6,255.7
1,163.83
-2,168.3
4,213.28
4,406.03
3,989.39
-1,608.87
-3,304.45
-3,902.23
-4,252.56
-4,831.29
-815.39
-2,099.19
Dividend per Share
- -
263.79
660.65
859.91
448.49
448.68
897.49
897.49
897.57
915.67
647.36
649.77
653.31
- -
Book Value per Share
53,604.76
56,901.77
61,862.8
62,658.18
61,811.74
61,617.12
68,689.03
68,289.06
69,787.71
73,133.33
72,809.8
69,666.36
66,800.37
67,126.6
Tangible Book Value per Share
52,020.65
55,214.74
59,620.89
60,977.72
60,429.31
60,425.44
67,012.28
66,084.65
65,703.88
66,383.51
57,252.32
53,236.27
51,724.79
52,244.72
Basic Weighted Avg Shares
8
8
9
9
9
9
9
9
9
9
9
9
10
10
Sales/Revenue/Turnover
500,967
578,640
567,940
560,535
555,027
567,434
612,311
586,728
593,228
635,393
663,980
697,869
808,780
860,936
Operating Margin (%)
7.94
8.53
9.48
2.65
4.3
6.95
9.24
5.79
2.63
2.7
1.68
-3.58
0.08
2.94
Depreciation Expense
20,401
24,919
23,979
21,519
21,724
20,036
20,488
19,965
19,950
20,870
26,343
29,142
32,831
31,306
Net Income, GAAP
-65,715
37,412
48,562
10,628
-5,396
8,009
70,913
27,103
12,816
13,552
11,122
-1,223
-28,592
8,690
Effective Tax Rate (%)
488.4
17.89
24
- -
- -
50.17
20.33
18.58
- -
27.09
66.33
- -
- -
50.59
Profit Margin (%)
-13.12
6.47
8.55
1.9
-0.97
1.41
11.58
4.62
2.16
2.13
1.68
-0.18
-3.54
1.01
Working Capital
177,021
275,727
291,343
175,371
193,246
157,501
237,204
314,527
255,462
320,131
155,797
340,233
212,531
150,320
LT Debt
274,353
321,019
228,116
39,894
59,892
69,953
113,821
153,893
156,112
247,148
165,965
395,791
304,727
219,669
Total Equity
439,361
488,337
553,773
589,222
581,193
579,363
645,858
642,097
656,379
690,111
699,526
708,808
671,649
674,030
Return on Invested Capital (%)
- -
4.64
4.35
- -
- -
2.51
5.42
3.23
- -
1.24
0.36
- -
- -
1.08
Return on Capital (%)
- -
5.65
6.46
- -
- -
1.47
9.37
3.68
- -
2.07
2.32
- -
- -
1
Return on Common Equity (%)
- -
8.07
9.32
1.86
-0.92
1.38
11.58
4.21
1.97
2.04
1.67
-0.18
-4.36
1.35

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
232,328
227,334
268,043
LT Borrowings
300,767
260,760
215,668
LT Finance Leases
3,961
4,119
4,001
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
481,068
422,397
327,406

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
617,971
556,978
569,956
Cash, Cash Equivalents & STI
289,817
228,848
213,434
Accounts Receivable, Net
128,386
121,165
143,865
Inventories
162,480
164,008
174,697
Total Current Liabilities
405,440
372,463
419,636
Payables & Accruals
- -
- -
- -
ST Debt
232,328
227,334
268,043
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.04%
0.96%
-5.24%
Free Cash Flow
-68.01%
12%
-82.11%
Net Income, GAAP
230.82%
412.38%
2,237.79%
Sales/Revenue/Turnover
3.74%
6.74%
15.89%
Total Cash Common Dividend
- -
- -
6.57%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
155,364
172,382
191,500
178,622
697,869
2025
182,087
193,994
215,928
216,771
808,780
2026
203,579
224,659
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1,613.45
35.48
-2,901.03
1,677.49
-134.67
2025
-808.57
-1,754.29
961.9
-1,241.4
-2,970.48
2026
898
283
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
649.77
2025
- -
- -
- -
- -
653.31
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jae-Hoon Jeong
Full Time Employees
1,685
Sector
Health technology
Industry
Pharmaceuticals: major
Address
64 Cheonhodaero Seoul SL South Korea 02587
IPO Date
Apr 8, 2013
Website
donga-st.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Dong-A ST Co., Ltd. (170900.KS) develops, manufactures, and markets pharmaceutical products and medical devices primarily in South Korea and internationally. The company offers a broad portfolio of ethical drugs including Stillen (eupatilin) for gastritis treatment; Zydena (udenafil) for erectile dysfunction; Motilitone (corydaline) for functional dyspepsia; Suganon (evogliptin) and Sugamet XR for type 2 diabetes mellitus; Closerin for tuberculosis; Dulastin PFS and Leucostim for neutropenia; Eporon for anemia; Terizidone for tuberculosis; vaccines; AIDS diagnostic kits; chemotherapeutic agents; nutrition and health drinks; and biosimilars such as IMULDOSA (ustekinumab-srlf, Stelara biosimilar), Grotropin growth hormone, and Darbepoetin alfa (DA-3880); alongside medical devices encompassing high-technology devices, custom-made products, artificial cardiac circuits for open-heart surgery, ECG monitoring platforms like Hicardi+ H100, and digital healthcare devices. Founded in 1932 and headquartered at 64 Cheonho-daero, Dongdaemun-gu, Seoul, South Korea, Dong-A ST operates through subsidiaries including STgen Bio for biosimilar CDMO services and Dong-A Chammed for ENT clinic equipment, respiratory care devices, and endoscopic solutions, with geographic reach spanning developed and emerging markets in Europe, the US, Asia, Latin America, the Middle East, and Africa. Recent developments include US FDA and European CHMP approval for IMULDOSA in 2024 with global launches by partners like Accord and Meiji; acquisition of Abtis Co. Ltd. and its Abclick platform for ADC drug development in 2025; partnerships such as a joint research agreement with NeuroBo Pharmaceuticals and ImmunoForge for a long-acting obesity drug formulation in 2024, licensing deals with Julphar for MENA biotechnology products, IMBiologics for novel antibodies, Intas Pharmaceuticals for DMB-3115, Polifarma for Darbepoetin alfa, Yangtze River for DA-7310, Eurofarma for Suganon and Dystalis, and XCOPRI for 30 countries; relocation of its Biotech Research Center to Songdo, Incheon; and expansions like Suganon launches in Thailand, Philippines, Brazil, and Russia.